Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Pharmos(PARS) -- Ignore unavailable to you. Want to Upgrade?

To: crysball who wrote (1480)	10/29/1998 9:03:00 PM
From: yosi s	Respond to of 1491

Currently tamoxiphen as adjuvent therapy is taken for 5 years. As for prevention ,time will tell if 5 years is enough or if you get benefit for taking it for ever. How ever if Pharmos wants to get that indication it will take many thousands of patients and very long follow up. It is much easier to show effectiveness in treating cancer and preventing recurrance, than showing it to prevent cancer in high risk population. Pharmos is on record to start Human studies in 1999. (Phase 1).